Philippe ClÃ©zardin

List of Publications by Year
in descending order

178 papers	9,938 citations	24978 57 h-index	39575 94 g-index
200 all docs	200 docs citations	200 times ranked	10698 citing authors

#	Article	IF	Citations
1	Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Research, 2002, 62, 6538-44.	0.4	421
2	Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. Journal of Clinical Investigation, 2004, 114, 1714-1725.	3.9	340
3	Bone metastases. Nature Reviews Disease Primers, 2020, 6, 83.	18.1	246
4	Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. Journal of Clinical Investigation, 2004, 114, 1714-1725.	3.9	222
5	Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity: Figure 1.. Cancer Research, 2005, 65, 4971-4974.	0.4	217
6	Integrin Î±vÎ²3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB Journal, 2002, 16, 1266-1268.	0.2	215
7	Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone Metastasis. Journal of the National Cancer Institute, 2007, 99, 322-330.	3.0	213
8	SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Research, 2003, 63, 3919-22.	0.4	198
9	Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer. Cancer Research, 2007, 67, 8742-8751.	0.4	188
10	Tumor Î±vÎ²3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases. Cancer Research, 2007, 67, 5821-5830.	0.4	186
11	The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9643-9648.	3.3	185
12	Bisphosphonates in cancer therapy. Cancer Letters, 2007, 257, 16-35.	3.2	183
13	A Cathepsin K Inhibitor Reduces Breast Cancerâ€“Induced Osteolysis and Skeletal Tumor Burden. Cancer Research, 2007, 67, 9894-9902.	0.4	180
14	Effects of Bone-Targeted Agents on Cancer Progression and Mortality. Journal of the National Cancer Institute, 2012, 104, 1059-1067.	3.0	171
15	Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 2016, 27, 379-390.	0.6	165
16	Increased Dickkopf-1 expression in breast cancer bone metastases. British Journal of Cancer, 2007, 97, 964-970.	2.9	159
17	Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. PLoS ONE, 2011, 6, e19234.	1.1	157
18	Bone metastasis: mechanisms, therapies, and biomarkers. Physiological Reviews, 2021, 101, 797-855.	13.1	153

#	Article	IF	Citations
19	Early Detection of Bone Metastases in a Murine Model Using Fluorescent Human Breast Cancer Cells: Application to the Use of the Bisphosphonate Zoledronic Acid in the Treatment of Osteolytic Lesions. Journal of Bone and Mineral Research, 2001, 16, 2027-2034.	3.1	148
20	Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class. Bone, 2011, 48, 71-79.	1.4	148
21	Direct and indirect anticancer activity of bisphosphonates: A brief review of published literature. Cancer Treatment Reviews, 2012, 38, 407-415.	3.4	147
22	miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasisâ€“Associated Genes. Cancer Research, 2018, 78, 5259-5273.	0.4	141
23	Interaction of platelet-derived autotaxin with tumor integrin Î±VÎ²3 controls metastasis of breast cancer cells to bone. Blood, 2014, 124, 3141-3150.	0.6	136
24	High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity In Vivo. Cancer Research, 2011, 71, 4562-4572.	0.4	134
25	Bone metastasis: pathogenesis and therapeutic implications. Clinical and Experimental Metastasis, 2007, 24, 599-608.	1.7	132
26	The HIF-1â€“Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth. Cancer Research, 2011, 71, 1647-1657.	0.4	132
27	Metastasis and bone loss: Advancing treatment and prevention. Cancer Treatment Reviews, 2010, 36, 615-620.	3.4	121
28	Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, S3-S9.	0.6	110
29	Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Research and Treatment, 2007, 101, 135-148.	1.1	105
30	Cancer Cell Expression of Autotaxin Controls Bone Metastasis Formation in Mouse through Lysophosphatidic Acid-Dependent Activation of Osteoclasts. PLoS ONE, 2010, 5, e9741.	1.1	101
31	Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene, 2013, 32, 724-735.	2.6	100
32	The antitumor potential of bisphosphonates. Seminars in Oncology, 2002, 29, 33-42.	0.8	100
33	Therapeutic targets for bone metastases in breast cancer. Breast Cancer Research, 2011, 13, 207.	2.2	97
34	Recent insights into the role of integrins in cancer metastasis. Cellular and Molecular Life Sciences, 1998, 54, 541-548.	2.4	94
35	A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, Î²-thromboglobulin and platelet factor 4 in healthy volunteers. Thrombosis Research, 1983, 29, 569-581.	0.8	91
36	In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes and Development, 2001, 15, 1373-1382.	2.7	90

#	Article	IF	Citations
37	Differential Effect of Doxorubicin and Zoledronic Acid on Intraosseous versus Extraosseous Breast Tumor Growth In vivo. Clinical Cancer Research, 2008, 14, 4658-4666.	3.2	90
38	TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3870-9.	3.3	90
39	Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. , 1999, 75, 538-546.		89
40	Anti-tumour activity of zoledronic acid. Cancer Treatment Reviews, 2005, 31, 1-8.	3.4	86
41	International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. European Journal of Cancer, 2007, 43, 852-858.	1.3	83
42	Complex formation of human thrombospondin with osteonectin. FEBS Journal, 1988, 175, 275-284.	0.2	81
43	Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity. Journal of Biological Chemistry, 2003, 278, 45826-45832.	1.6	81
44	Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone, 2011, 48, 259-266.	1.4	81
45	In Vitro and In Vivo Antitumor Effects of Bisphosphonates. Current Medicinal Chemistry, 2003, 10, 173-180.	1.2	80
46	Cancer Cell Colonisation in the Bone Microenvironment. International Journal of Molecular Sciences, 2016, 17, 1674.	1.8	80
47	Bone-Targeted Therapies in Cancer-Induced Bone Disease. Calcified Tissue International, 2018, 102, 227-250.	1.5	80
48	Increased expression and serum levels of the stromal cellâ€secreted protein periostin in breast cancer bone metastases. International Journal of Cancer, 2011, 128, 352-360.	2.3	79
49	One-step procedure for the rapid isolation of mouse monoclonal antibodies and their antigen binding fragments by fast protein liquid chromatography on a mono Q anion-exchange column. Journal of Chromatography A, 1985, 319, 67-77.	1.8	78
50	Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. , 1999, 83, 263-269.		78
51	The role of osteoclasts in breast cancer bone metastasis. Journal of Bone Oncology, 2016, 5, 93-95.	1.0	72
52	Cathepsin K inhibitors as treatment of bone metastasis. Current Opinion in Supportive and Palliative Care, 2008, 2, 218-222.	0.5	71
53	Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. British Journal of Cancer, 2012, 107, 63-70.	2.9	70
54	Dual Function of ERRÎ± in Breast Cancer and Bone Metastasis Formation: Implication of VEGF and Osteoprotegerin. Cancer Research, 2011, 71, 5728-5738.	0.4	68

#	Article	IF	Citations
55	Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. BoneKEy Reports, 2013, 2, 267.	2.7	67
56	Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. Journal of Cellular Biochemistry, 1997, 67, 75-83.	1.2	65
57	Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. British Journal of Haematology, 1985, 60, 331-344.	1.2	63
58	TWIST1 Expression in Breast Cancer Cells Facilitates Bone Metastasis Formation. Journal of Bone and Mineral Research, 2014, 29, 1886-1899.	3.1	63
59	Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1in vivo. International Journal of Cancer, 2005, 116, 686-691.	2.3	62
60	How Do Bisphosphonates Inhibit Bone Metastasis In Vivo. Neoplasia, 2010, 12, 571-578.	2.3	59
61	The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. Oncotarget, 2015, 6, 20604-20620.	0.8	56
62	Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. International Journal of Oncology, 2012, 40, 1133-1141.	1.4	55
63	Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone. Cancer Research, 2017, 77, 268-278.	0.4	55
64	Thrombospondin is synthesized and secreted by human osteoblasts and osteosarcoma cells. A model to study the different effects of thrombospondin in cell adhesion. FEBS Journal, 1989, 181, 721-726.	0.2	54
65	Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate, 2012, 72, 713-720.	1.2	54
66	Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene, 2021, 40, 1284-1299.	2.6	53
67	Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Research, 2005, 65, 300-8.	0.4	52
68	Advances in optical imaging and novel model systems for cancer metastasis research. Clinical and Experimental Metastasis, 2007, 24, 699-705.	1.7	50
69	P49. Zoledronic acid-induced IPP accumulation in cancer cells strongly correlates with Î³Î´ T-cell mediated cancer cell death. Cancer Treatment Reviews, 2008, 34, 37.	3.4	50
70	Platelet is a major contributor to circulating levels of Dickkopfâ€1: clinical implications in patients with multiple myeloma. British Journal of Haematology, 2009, 145, 264-266.	1.2	49
71	Bisphosphonates in preclinical bone oncology. Bone, 2011, 49, 66-70.	1.4	48
72	Lysophosphatidic Acid Receptor Type 1 (LPA1) Plays a Functional Role in Osteoclast Differentiation and Bone Resorption Activity. Journal of Biological Chemistry, 2014, 289, 6551-6564.	1.6	48

#	Article	IF	Citations
73	In VivoPhosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vî³9Vî´2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement. Clinical Cancer Research, 2012, 18, 6249-6259.	3.2	46
74	Isolation of thrombospondin released from thrombinstimulated human platelets by fast protein liquid chromatography on an anion-exchange mono-q column. Journal of Chromatography A, 1984, 296, 249-256.	1.8	42
75	Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo. Cancer Research, 2008, 68, 8945-8953.	0.4	42
76	Bioactive Lipids Lysophosphatidic Acid and Sphingosine 1-Phosphate Mediate Breast Cancer Cell Biological Functions Through Distinct Mechanisms. Oncology Research, 2009, 18, 173-184.	0.6	41
77	Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. Biomaterials, 2009, 30, 6367-6373.	5.7	40
78	The Molecular Basis of Bisphosphonate Activity: A Preclinical Perspective. Seminars in Oncology, 2010, 37, S3-S11.	0.8	38
79	Pathophysiology of bone metastases from solid malignancies. Joint Bone Spine, 2017, 84, 677-684.	0.8	38
80	Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. Bone, 2018, 108, 202-209.	1.4	38
81	Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Research, 2012, 32, 5211-20.	0.5	37
82	Integrins in Bone Metastasis Formation and Potential Therapeutic Implications. Current Cancer Drug Targets, 2009, 9, 801-806.	0.8	36
83	Tumour-derived miRNAs and bone metastasis. BoneKEy Reports, 2015, 4, 688.	2.7	36
84	Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy. Current Pharmaceutical Design, 2010, 16, 3007-3014.	0.9	35
85	Transmigration: A New Property of Mature Multinucleated Osteoclasts. Journal of Bone and Mineral Research, 2006, 21, 1913-1923.	3.1	34
86	A Transcriptome-proteome Integrated Network Identifies Endoplasmic Reticulum thiol oxidoreductase (ERp57) as a Hub that Mediates Bone Metastasis. Molecular and Cellular Proteomics, 2013, 12, 2111-2125.	2.5	32
87	Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1. Biochemical Journal, 1997, 321, 819-827.	1.7	31
88	Cell Membrane Proteomic Analysis Identifies Proteins Differentially Expressed in Osteotropic Human Breast Cancer Cells. Neoplasia, 2008, 10, 1014-IN11.	2.3	31
89	Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate, 2013, 73, 1738-1746.	1.2	31
90	Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). BoneKEy Reports, 2014, 3, 580.	2.7	31

#	Article	IF	Citations
91	The RANKâ€“RANKL axis: an opportunity for drug repurposing in cancer?. Clinical and Translational Oncology, 2019, 21, 977-991.	1.2	31
92	Characterization of two murine monoclonal antibodies (P10, P12) directed against different determinants on human blood platelet thrombospondin. FEBS Journal, 1986, 154, 95-102.	0.2	30
93	A convenient clinically relevant model of human breast cancer bone metastasis. Clinical and Experimental Metastasis, 2008, 25, 33-42.	1.7	30
94	Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. Oncotarget, 2016, 7, 77071-77086.	0.8	29
95	Osteonectin is an Î±-granule component involved with thrombospondin in platelet aggregation. Journal of Bone and Mineral Research, 1991, 6, 1059-1070.	3.1	28
96	Emerging therapies in bone metastasis. Current Opinion in Pharmacology, 2015, 22, 79-86.	1.7	28
97	Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 102-113.	0.9	26
98	A New Murine Model of Osteoblastic/Osteolytic Lesions from Human Androgen-Resistant Prostate Cancer. PLoS ONE, 2013, 8, e75092.	1.1	26
99	ERRÎ± promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene, 2019, 38, 950-964.	2.6	25
100	Identification of Heparin-Binding EGF-Like Growth Factor (HB-EGF) as a Biomarker for Lysophosphatidic Acid Receptor Type 1 (LPA1) Activation in Human Breast and Prostate Cancers. PLoS ONE, 2014, 9, e97771.	1.1	24
101	Low-Intensity Ultrasound Promotes Clathrin-Dependent Endocytosis for Drug Penetration into Tumor Cells. Ultrasound in Medicine and Biology, 2015, 41, 2740-2754.	0.7	24
102	The CaSR in Pathogenesis of Breast Cancer: A New Target for Early Stage Bone Metastases. Frontiers in Oncology, 2020, 10, 69.	1.3	24
103	Nonâ€coding RNAs in bone remodelling and bone metastasis: Mechanisms of action and translational relevance. British Journal of Pharmacology, 2021, 178, 1936-1954.	2.7	24
104	Development of a New ELISA for Serum Periostin: Evaluation of Growth-Related Changes and Bisphosphonate Treatment in Mice. Calcified Tissue International, 2010, 87, 341-350.	1.5	23
105	Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. Journal of Proteome Research, 2012, 11, 2247-2260.	1.8	23
106	Tandem purification of IgM monoclonal antibodies from mouse ascites fluids by anion-exchange and gel fast protein liquid chromatography. Journal of Chromatography A, 1986, 354, 425-433.	1.8	22
107	Expression and localisation of Î±v integrins in human odontoblasts. Cell and Tissue Research, 2006, 323, 457-463.	1.5	22
108	Structural and immunological comparison of human thrombospondins isolated from platelets and from culture supernatants of endothelial cells and fibroblasts. Evidence for a thrombospondin polymorphism. FEBS Journal, 1986, 159, 569-579.	0.2	21

#	Article	IF	Citations
109	Thrombospondin in Milk, Other Breast Secretions, and Breast Tissue. Seminars in Thrombosis and Hemostasis, 1987, 13, 378-384.	1.5	21
110	Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. International Journal of Cancer, 2014, 135, 1319-1329.	2.3	21
111	TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. Cancer Letters, 2018, 438, 32-43.	3.2	21
112	Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. Oncotarget, 2017, 8, 56460-56472.	0.8	21
113	CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. Cell Biochemistry and Function, 1998, 16, 211-221.	1.4	17
114	Thrombospondin (TSP1) mediates in vitro proliferation of human MG-63 osteoblastic cells induced by Î±-thrombin. FEBS Letters, 1993, 329, 341-346.	1.3	16
115	Unseeded Inertial Cavitation for Enhancing the Delivery ofÂChemotherapies: A Safety Study. Ultrasound in Medicine and Biology, 2016, 42, 220-231.	0.7	16
116	Identification and characterization of fragments of major glycoproteins from platelet membrane after chymotrypsin treatment. FEBS Journal, 1985, 148, 97-106.	0.2	15
117	Platelet-Osteosarcoma Cell Interaction is Mediated Through a Specific Fibrinogen-Binding Sequence Located Within the N-Terminal Domain of Thrombospondin 1. Journal of Bone and Mineral Research, 2010, 15, 361-368.	3.1	15
118	Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. BoneKEy Reports, 2015, 4, 744.	2.7	15
119	Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer. Scientific Reports, 2015, 5, 16354.	1.6	14
120	Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFÎ²/CTGF Axis. Cells, 2021, 10, 430.	1.8	14
121	Tryptic peptide map analysis of the major human blood platelet membrane glycoproteins separated by two-dimensional polyacrylamide gel electrophoresis. Biochimica Et Biophysica Acta - Biomembranes, 1982, 689, 513-522.	1.4	13
122	Tandem separation of labelled human blood platelet membrane glycoproteins by anion-exchange and gel fast protein liquid chromatography. Journal of Chromatography A, 1985, 326, 179-190.	1.8	13
123	ERRÎ± Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response. Cancer Research, 2020, 80, 2914-2926.	0.4	13
124	Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. Frontiers in Oncology, 2020, 10, 712.	1.3	13
125	Tandem purification of mouse IgM monoclonal atibodies produced in vitro using anion-exchange and gel fast protein liquid chromatography. Journal of Chromatography A, 1986, 358, 209-218.	1.8	12
126	The growth-supportive effect of thrombospondin (TSP1) and the expression of TSP1 by human MG-63 osteoblastic cells are both inhibited by dexamethasone. FEBS Letters, 1993, 335, 161-166.	1.3	11

#	Article	IF	Citations
127	Localization of thrombospondin, CD36 and CD51 during prenatal development of the human mammary gland. Differentiation, 1994, 57, 133-141.	1.0	11
128	Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vî³9Vî´2 T cell cytotoxicity in PC-3 prostate cancer cells. Cancer Letters, 2015, 357, 279-285.	3.2	11
129	MicroRNAs and Their Roles in Breast Cancer Bone Metastasis. Current Osteoporosis Reports, 2021, 19, 256-263.	1.5	10
130	The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis. Calcified Tissue International, 2018, 103, 567-580.	1.5	10
131	Fracture Risk Evaluation of Bone Metastases: A Burning Issue. Cancers, 2021, 13, 5711.	1.7	10
132	Cell attachment and fibrinogen binding properties of platelet and endothelial cell thrombospondin are not affected by structural differences in the 70 and 18 kDa protease-resistant domains. FEBS Letters, 1988, 228, 215-218.	1.3	8
133	Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. Clinical Breast Cancer, 2018, 18, e1311-e1321.	1.1	8
134	Bone metastases in the era of targeted treatments: insights from molecular biology. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 98-111.	0.4	8
135	MicroRNA-mediated regulation of bone metastasis formation: from primary tumors to skeleton. , 2015, , 479-489.		6
136	Production, Characterization, and Use of Monoclonal Antibodies Directed Against Human Blood Platelet Thrombospondin: Immunologic Comparison with Human Endothelial and Fibroblast Thrombospondins. Seminars in Thrombosis and Hemostasis, 1987, 13, 261-275.	1.5	4
137	Insights into the antitumor effects of bisphosphonates from preclinical models and potential clinical implications. IBMS BoneKEy, 2009, 6, 210-217.	0.1	4
138	Structural and immunological differences between human platelet and endothelial thrombospondins. FEBS Letters, 1986, 196, 49-53.	1.3	3
139	Editorial [Hot-topic: Molecularly Targeted Therapies in Breast Cancer Bone Metastases (Executive) Tj ETQq1 1 0.784314 rgBT /Overlo	0.9	3
140	Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?. Future Oncology, 2015, 11, 2853-2856.	1.1	3
141	Frequent low-dose bisphosphonate therapy. Bone, 2007, 41, 901-902.	1.4	2
142	Early Bone Metastasis-Associated Molecular and Cellular Events. , 2010, , 41-45.		2
143	1074 POSTER Effects of Zoledronic Acid and Denosumab on Human Vγ9Vδ2 T-cell-Mediated Cell Death of RANK-Expressing Breast Cancer Cells. European Journal of Cancer, 2011, 47, S117.	1.3	2
144	RANK/RANKL pathway in cancer: Biological activity beyond bone?. Journal of Bone Oncology, 2012, 1, 67-68.	1.0	2

#	Article	IF	Citations
145	Effect of intra-tibial injection on mechanical properties of mouse bone. Computer Methods in Biomechanics and Biomedical Engineering, 2017, 20, S57-S58.	0.9	2
146	Impact of Anti-Angiogenic Treatment on Bone Vascularization in a Murine Model of Breast Cancer Bone Metastasis Using Synchrotron Radiation Micro-CT. Cancers, 2022, 14, 3443.	1.7	2
147	Continuous or repeated intermittent low-dose therapy with zoledronic acid induces a sustained inhibition of tumor cell trafficking to bone in vivo. Bone, 2006, 38, 44-45.	1.4	1
148	A cathepsin k inhibitor (alone or in combination with zoledronic acid) inhibits the progression of breast cancer bone metastases. Bone, 2006, 38, 55-56.	1.4	1
149	Expression of lysophospholipase D/autotaxin by breast cancer cells controls bone metastasis formation by increasing osteoclast differentiation. Bone, 2010, 46, S41.	1.4	1
150	Can bisphosphonates really reduce the risk of recurrences in early breast cancer?. IBMS BoneKEy, 2011, 8, 159-164.	0.1	1
151	Physiopathologie des mÃ©tastases osseuses des tumeurs solides. Revue Du Rhumatisme Monographies, 2017, 84, 107-114.	0.0	1
152	Abstract 1448: Disseminated tumor cell formation promoted by lysophosphatidic acid (LPA) involves ZEB1/miR21-dependent activation pathway. , 2014, , .		1
153	Abstract P6-13-19: Adding zoledronic acid to neo-adjuvant chemotherapy may improve the efficiency of chemotherapy in locally advanced breast cancer: Results from the prospective randomized study NEOZOL. , 2016, , .		1
154	Effect of Thrombospondin on Platelet ADP-Induced Aggregation and 125I-Fibrinogen Binding. European Heart Journal, 1983, 4, 5-5.	1.0	0
155	Antitumour Effects of Bisphosphonates. , 2006, , 345-350.		0
156	1302 POSTER Updated International Society of Geriatric Oncology (SIOG) recommendations for the use of bisphosphonates in elderly cancer patients with bone metastases. European Journal of Cancer, Supplement, 2007, 5, 174.	2.2	0
157	PathogÃ©nie des mÃ©tastases osseuses. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 327-331.	0.0	0
158	P20. Autotaxin promotes metastasis dissemination of breast cancer cells. Cancer Treatment Reviews, 2008, 34, 20-21.	3.4	0
159	P56. Targeting VEGF and its receptors in the treatment of breast cancer bone metastases. Cancer Treatment Reviews, 2008, 34, 41.	3.4	0
160	P57. Manipulating the bone mineral affinity of bisphosphonates to directly target cancer cells in the bone marrow. Cancer Treatment Reviews, 2008, 34, 42.	3.4	0
161	Physiopathologie des mÃ©tastases osseuses. Oncologie, 2009, 11, 10-15.	0.2	0
162	Development of a new ELISA for serum periostin: Growth-related changes and effects of bisphosphonate in mice. Bone, 2009, 44, S270.	1.4	0

#	Article	IF	Citations
163	Involvement of the Slit2/Robo1 Pathway in Breast Cancer Bone Metastasis. Bone, 2010, 46, S37.	1.4	0
164	Zoledronic acid induces IPP release from cancer cells which causes Vgamma9Vdelta2 T cell expansion in PBMCs. Bone, 2010, 46, S40-S41.	1.4	0
165	Frequent Intermittent Low-dose Therapy Accentuates the Antitumour Activity of the Bisphosphonate Risedronate In Vivo. Bone, 2010, 46, S43.	1.4	0
166	5007 ORAL The MicroRNAs-30 Family Interferes With the Formation of Breast Cancer Bone Metastases by Targeting Osteomimetic Genes. European Journal of Cancer, 2011, 47, S332.	1.3	0
167	Zoledronic acid induces IPP accumulation and release from human cancer cells, which activates VÎ³9VÎ´2 T cell-differentiation and migration in vitro and mediates VÎ³9VÎ´2 T cell-induced cancer cell death in vivo. Bone, 2011, 48, S46.	1.4	0
168	Clinical and basic research papers â€“ February 2011. IBMS BoneKEy, 2011, 8, 65-73.	0.1	0
169	Clinical and basic research papers â€“ July 2011. IBMS BoneKEy, 2011, 8, 305-312.	0.1	0
170	Clinical and basic research papers â€“ November-December 2011. IBMS BoneKEy, 2011, 8, 305-312.	0.1	0
171	Clinical and basic research papers â€“ September 2011. IBMS BoneKEy, 2011, 8, 390-396.	0.1	0
172	Clinical and basic research papers â€“ October 2011. IBMS BoneKEy, 2011, 8, 428-432.	0.1	0
173	Bioluminescence Imaging of Prenylation Inhibitionâ€“Letter. Clinical Cancer Research, 2012, 18, 6077-6077.	3.2	0
174	562 Lysophosphatidic acid-induced breast cancer metastasis depends on LPA1/ZEB1/miR-21-activation pathway. European Journal of Cancer, 2014, 50, 182.	1.3	0
175	Bone Metastases; Basic Aspects. , 2019, , 304-309.		0
176	Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors. , 2020, , 403-420.		0
177	MicroRNAs and bone metastasis. , 2022, , 457-469.		0
178	Abstract P5-04-13: Antibody-based therapy targeting integrin a5 is an effective strategy to treat experimental breast cancer bone metastasis. , 2013, , .		0